Funding of 19.96M SEK to conduct an RCT of Montelukast for treating Parkinson’s disease has been awarded to the group. Link for more information can be found here.
Link to the news article can be found here
Our paper peeling back the pharmacology behind the new antipsychotic SEP-856 (Ulotaront) can be accessed here
Link to Per’s page can be found here
Per Svenningsson is now a board member of the editorial team for Molecular Psychiatry. Visit the following link to see all members: https://www.nature.com/mp/editors/editorial-board